



Pereira, Joana R. P. ^{A, B*}; Antunes, Mónica ^C; Neng, Nuno R. ^{A, B}; Mustra, Carla ^D; Franco, João ^E; Fonseca, Suzana ^{A, E}

A - Laboratório de Ciências Forenses e Psicológicas Egas Moniz, Egas Moniz Center for Interdisciplinary Research, Egas Moniz School of Health & Science, Quinta da Granja, 2829-511 Caparica, Almada, Portugal.


B - Centro de Química Estrutural, Institute of Molecular Sciences, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, 1749 -016 Lisboa, Portugal.

C - CICS-UBI – Health Sciences Research Centre, Faculty of Health Sciences, University of Beira Interior, 6201-506 Covilhã, Portugal


D - Forensic Chemistry and Toxicology Service, Centre Branch of National Institute of Legal Medicine and Forensic Sciences, 3000-548 Coimbra, Portugal

E - Forensic Chemistry and Toxicology Service, South Branch of National Institute of Legal Medicine and Forensic Sciences, 1169-201 Lisboa, Portugal

INTRODUCTION




New Psychoactive Substances (NPS) are a real contemporaneous threat, due to their potency, dangerousness, and lack of control/monitoring. The NPS group that has grown the most in the last years is the **synthetic opioids** group, where **fentanyl and its analogues** stand out. However, the emerging concerning synthetic opioids are **nitazenes**. Due to their high potency, even minimal consumption doses can lead to severe health effects or even fatal overdoses, making them a public health issue^{1,2}. Notwithstanding, it is also important to remain vigilant towards more “traditional” psychoactive substances like **hallucinogens**, as they have been associated with poisonings/intoxications³. This is particularly relevant now that they are also being used for clinical purposes¹. Therefore, it is essential to establish analytical methodologies for monitoring these compounds in biological matrices.



OBJECTIVE



The aim of this study was to **develop, optimize** and **validate** an **easy** to use, **fast, simple**, and **sensitive** method for **routine** analysis of **6** new synthetic opioids (fentanyls and nitazenes) and **3** hallucinogens in **postmortem and/or in vivo** whole blood.



METHODOLOGY

Optimized using Full Factorial Design of Experiments

MAIN RESULTS




Figure 2: Overlaid extracted ion chromatograms of the target analytes of final method.

Selectivity:
No endogenous or exogenous (> 200 drugs) interferences

Validation according to ANSI/ASB Standard 036.

Ionization Suppression/Enhancement:
Between - 25 % and 25 %
CV % < 20 %

Table 1: LOD, LLOQ, and Calibration Model validation parameters obtained for each target analyte.

Substance	LOD (ng/mL)	LLOQ (ng/mL)	Linear Range (ng/mL)	Weighting Factor	Average r ²
Carfentanil	0.05	0.1	0.1 – 20	1/x	0.9951
Fentanyl	0.05	0.1	0.1 – 20	1/x	0.9958
Isotonitazene	0.05	0.1	0.1 – 20	1/x	0.9962
LSD	0.05	0.1	0.1 – 20	1/x	0.9955
LSD-OH	0.05	0.1	0.1 – 20	1/x	0.9963
Mescaline	1	2.5	2.5 – 500	1/x	0.9935
Metonitazene	0.1	0.1	0.1 – 20	1/x	0.9963
Norfentanyl	0.1	0.1	0.1 – 20	1/x	0.9949
Sufentanil	0.05	0.1	0.1 – 20	1/x	0.9962

Table 2: Maximum precision and accuracy values obtained for each target analyte (3 concentration levels).

Substance	Precision (CV %)		Accuracy (Bias %)	
	Intra-day (n = 3)	Inter-day (n = 15)	Intra-day (n = 3)	Inter-day (n = 15)
Carfentanil	8,42	14,67	15,34	5,88
Fentanyl	8,58	11,18	12,99	4,61
Isotonitazene	9,88	15,46	19,13	6,62
LSD	9,18	10,23	-15,73	-9,97
LSD-OH	11,74	13,43	19,42	-5,87
Mescaline	10,67	15,20	17,79	-9,87
Metonitazene	9,86	10,14	17,00	10,14
Norfentanyl	9,83	16,65	19,74	12,20
Sufentanil	8,89	17,79	19,17	10,43

Precipitation Solvent Volume



↔ 100 µL
↔ 150 µL
↔ 200 µL

% Formic Acid



↔ 0,1 %
↔ 0,3 %
↔ 0,5 %


Centrifugation Time



↔ 2 min.
↔ 5 min.
↔ 10 min.

Figure 3: Protein precipitation parameters optimized by full factorial design of experiments.

CONCLUSION



- This is a valuable and powerful method for toxicology laboratories, enabling the simultaneous identification, confirmation, and quantification of two different families of psychoactive substances, whether in postmortem or *in vivo* samples.
- Its speed, simplicity, effectiveness, and reliability make it particularly advantageous for routine implementation.

REFERENCES

- [1] United Nations Office on Drugs and Crime. **World Drug Report 2024**. Vienna; 2024.
- [2] European Monitoring Centre for Drugs and Drug Addiction. **European Drug Report 2024: Trends and Developments**. Lisbon; 2024.
- [3] Schlag AK *et al* (2022) *J Psychopharmacol* **36** (3): 258-272.

ACKNOWLEDGMENTS:

Centro de Química Estrutural is a Research Unit funded by Fundação para a Ciência e a Tecnologia through projects UIDB/00100/2020 (<https://doi.org/10.54499/UIDB/00100/2020>) and UIDP/00100/2020 (<https://doi.org/10.54499/UIDP/00100/2020>). Institute of Molecular Sciences is an Associate Laboratory funded by Fundação para a Ciência e a Tecnologia through project LA/P/0056/2020 (<https://doi.org/10.54499/LA/P/0056/2020>). CiiEM has provided support through Project 10.54499/UIDB/04585/2020, funded by FCT.